

Implanet announces the appointment of Brian Kwon, MD, as Medical Advisor for the United States

Bordeaux, Boston, November 12, 2014: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces the appointment of Brian Kwon, MD as Medical Advisor in the United States.


An orthopedic surgeon specializing in the surgical management of adult spine disorders at New England Baptist Hospital in Boston, Dr. Kwon holds a teaching appointment at Tufts University School of Medicine as Assistant Clinical Professor of Orthopedic Surgery. Dr. Kwon notably serves on the editorial board for the *Journal of Spinal Disorders & Techniques*, a preeminent peer-reviewed multidisciplinary journal for spine clinicians. Dr. Kwon will assist Implanet in its approach to the adult degenerative spine market in the United States and in the use of its JAZZ technology platform.

"The JAZZ implant developed by Implanet is a major innovation in the treatment of patients with degenerative spine disorders. Its technical properties give it substantial clinical value, notably in caring for my patients. I am pleased to have the opportunity to assist the company with its development efforts and am delighted to provide my experience in order to accelerate the adoption of this technology in the United States", says Dr. Kwon.

Alain Meunier, PhD, Implanet's Clinical & Scientific Affairs Director, adds: *"Dr. Kwon's contribution to recent breakthroughs in spine surgery is an invaluable asset to Implanet. This appointment goes hand in hand with the recent positive two-year clinical results of JAZZ¹ in degenerative indications and with an in-vitro biomechanical study conducted in the Orthopedic Biomechanics Laboratory at the Mayo Clinic (Rochester, MN, USA), showing JAZZ's efficiency in protecting pedicle screws implanted in osteoporotic vertebrae. Inserting JAZZ implants in adult degenerative scoliosis surgery appears to be an efficient solution for elderly patients, who are more difficult to treat because of their fragility and numerous related pathologies. Peer reviewed literature documents sublaminar band technology allows a significant reduction in operating time and blood loss along with atraumatic reduction in deformities that are often extremely rigid and the efficient securing of pedicle screws in assemblies with a high risk of post-operative mechanical failure."*

Implanet announces that it is attending the North American Spine Society (NASS) Annual Meeting, Nov 12 – 14, in San Francisco, California

NASS provides an opportunity for spine professionals to meet and share information, techniques, innovative procedures and best practices in the field of spine surgery. Implanet will be attending this major event to present its latest innovations to professionals from around the world.



Implanet
JAZZ



¹ White Paper The Jazz system: Spinal Deformity Treatment in older-aged Patients using the JAZZ Sublaminar Implant, available on the Company's website: www.implanet.com

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.
Ticker: IMPL - ISIN code: FR0010458729



IMPLANET

Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com

NewCap

Investor Relations
Florent Alba
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr

NewCap

Press Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr